Skip to main content
EJNMMI Reports
Fig. 1 | European Journal of Hybrid Imaging

Fig. 1

From: Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study

Fig. 1

Example cases. Two patients with a low (left; SSTR-TVbaseline change -95% and TL-SSTRbaseline change -97%) and high (right; SSTR-TVbaseline change 16% and TL-SSTRbaseline change 25%) residual tumor burden following PRRT. The automatically derived tumor VOI’s used to calculate SSTR-TV and TL-SSTR are visualized in red. The patient on the left (female, 51 yo) had a grade 2 tumor of unknown primary (Ki67 4–6%); the patient on the right (female, 57 yo) had a grade 1 small intestine neuroendocrine tumor (Ki67 2%). Both patients had > 25% liver tumor load. Consequently, the patient on the left had a long time-to-new treatment (17.5 months), while the patient on the right required additional treatment rather quickly, because of progressive disease under PRRT (new intrathoracic and intra-abdominal lymph node metastases)

Back to article page